Brief: Organogenesis Receives FDA Clearance For Next Generation Puraply Surgical Solution
15/08/2022 12:50
Aug 15 (Reuters) - Organogenesis Holdings Inc ORGO.O :
* ORGANOGENESIS RECEIVES FDA CLEARANCE FOR NEXT GENERATION
PURAPLY
SURGICAL SOLUTION
Source text for Eikon: ID:nGNX8Mv0Wc
Further company coverage: ORGO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers